JP2005535698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535698A5 JP2005535698A5 JP2004527153A JP2004527153A JP2005535698A5 JP 2005535698 A5 JP2005535698 A5 JP 2005535698A5 JP 2004527153 A JP2004527153 A JP 2004527153A JP 2004527153 A JP2004527153 A JP 2004527153A JP 2005535698 A5 JP2005535698 A5 JP 2005535698A5
- Authority
- JP
- Japan
- Prior art keywords
- modafinil
- crl
- solvate
- dose
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 93
- 229960001165 modafinil Drugs 0.000 claims 54
- 239000012453 solvate Substances 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 18
- 239000002904 solvent Substances 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 8
- 206010022437 insomnia Diseases 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- 208000032140 Sleepiness Diseases 0.000 claims 6
- 206010041349 Somnolence Diseases 0.000 claims 6
- 230000037321 sleepiness Effects 0.000 claims 6
- 239000006104 solid solution Substances 0.000 claims 6
- 238000010438 heat treatment Methods 0.000 claims 5
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 4
- 206010020765 hypersomnia Diseases 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 201000003631 narcolepsy Diseases 0.000 claims 4
- 201000002859 sleep apnea Diseases 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 238000004807 desolvation Methods 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000002948 appetite stimulant Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000005013 brain tissue Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- QBKFLYWZRMHHRS-UHFFFAOYSA-N chloroform;1,4-dioxane Chemical compound ClC(Cl)Cl.C1COCCO1 QBKFLYWZRMHHRS-UHFFFAOYSA-N 0.000 claims 2
- NWSBNVVOFKKFNV-UHFFFAOYSA-N chloroform;oxolane Chemical compound ClC(Cl)Cl.C1CCOC1 NWSBNVVOFKKFNV-UHFFFAOYSA-N 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 239000006194 liquid suspension Substances 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims 1
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 206010013954 Dysphoria Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000020595 eating behavior Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- -1 lyophilizates Substances 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40206402P | 2002-08-09 | 2002-08-09 | |
| US60/402,064 | 2002-08-09 | ||
| US10/635,445 | 2003-08-07 | ||
| US10/635,445 US6992219B2 (en) | 2002-08-09 | 2003-08-07 | Modafinil polymorphic forms |
| PCT/IB2003/003215 WO2004014846A1 (en) | 2002-08-09 | 2003-08-08 | Modafinil polymorphic forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010235766A Division JP5307106B2 (ja) | 2002-08-09 | 2010-10-20 | モダフィニル多形相 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005535698A JP2005535698A (ja) | 2005-11-24 |
| JP2005535698A5 true JP2005535698A5 (https=) | 2006-09-07 |
| JP4718177B2 JP4718177B2 (ja) | 2011-07-06 |
Family
ID=31720568
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004527153A Expired - Fee Related JP4718177B2 (ja) | 2002-08-09 | 2003-08-08 | モダフィニル多形相 |
| JP2010235766A Expired - Fee Related JP5307106B2 (ja) | 2002-08-09 | 2010-10-20 | モダフィニル多形相 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010235766A Expired - Fee Related JP5307106B2 (ja) | 2002-08-09 | 2010-10-20 | モダフィニル多形相 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6992219B2 (https=) |
| EP (2) | EP1575915A1 (https=) |
| JP (2) | JP4718177B2 (https=) |
| CN (3) | CN102875430A (https=) |
| AU (1) | AU2003253128B2 (https=) |
| CA (4) | CA2494010C (https=) |
| IL (3) | IL166301A (https=) |
| MX (1) | MXPA05001506A (https=) |
| NZ (1) | NZ537840A (https=) |
| WO (1) | WO2004014846A1 (https=) |
| ZA (1) | ZA200500411B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2277937T3 (es) | 2000-07-27 | 2007-08-01 | Teva Pharmaceutical Industries Ltd. | Modafinilo puro y cristalino y su procedimiento de preparacion. |
| WO2002092094A1 (en) * | 2001-03-27 | 2002-11-21 | Sumitomo Pharmaceuticals Co., Ltd. | Crystalline isoxazole derivative and medical preparation thereof |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| FR2849029B1 (fr) * | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| MXPA05008088A (es) * | 2003-02-24 | 2005-09-21 | Mallinckrodt Inc | Proceso mejorado para preparar benzhidril tioacetamida. |
| WO2004083183A1 (en) * | 2003-03-21 | 2004-09-30 | Hetero Drugs Limited | Novel crystalline forms of aripiprazole |
| WO2004085416A1 (en) * | 2003-03-24 | 2004-10-07 | Hetero Drugs Limited | Novel crystalline forms of (s)-citalopram oxalate |
| WO2004085426A1 (en) * | 2003-03-27 | 2004-10-07 | Hetero Drugs Limited | Novel crystalline forms of candesartan cilexetil |
| WO2004087660A1 (en) * | 2003-04-02 | 2004-10-14 | Hetero Drugs Limited | A novel process for amorphous form of donepezil hydrochloride |
| AU2003245029A1 (en) * | 2003-04-16 | 2004-11-04 | Hetero Drugs Limited | Novel crystalline forms of donepezil hydrochloride |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| ES2330321T3 (es) | 2003-05-16 | 2009-12-09 | Cephalon France | Procedimiento de sintesis de modafinilo. |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| PT1673370E (pt) | 2003-10-16 | 2009-11-05 | Symed Labs Ltd | Forma cristalina de linezolida |
| US20090018202A1 (en) * | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
| EP2292213A1 (en) * | 2004-02-06 | 2011-03-09 | Cephalon, Inc. | Compositions comprising a polymorphic form of armodafinil |
| WO2005099822A2 (en) * | 2004-04-13 | 2005-10-27 | Cephalon, Inc. | Reduction of drug / drug interactions with modafinil |
| WO2005099353A2 (en) * | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| EP1755388B1 (en) * | 2004-05-28 | 2010-10-06 | Transform Pharmaceuticals, Inc. | Mixed co-crystals and pharmaceutical compositions comprising the same |
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| WO2006018853A2 (en) | 2004-08-19 | 2006-02-23 | Hetero Drugs Limited | Novel polymorphs of efavirenz |
| AU2006272874B2 (en) * | 2005-07-21 | 2010-03-11 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| US7518019B2 (en) * | 2006-06-01 | 2009-04-14 | Hetero Drugs Limited | Processes for preparing sertraline hydrochloride crystalline forms |
| AU2007272501A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Pharma International Limited | Nanoparticulate formulations of modafinil |
| WO2008021341A2 (en) * | 2006-08-14 | 2008-02-21 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based treatment for premature ejaculation |
| UA110598C2 (uk) | 2006-11-10 | 2016-01-25 | Басф Се | Спосіб одержання кристалічної модифікації фіпронілу |
| NZ576524A (en) | 2006-11-10 | 2012-01-12 | Basf Se | Crystalline modification of fipronil |
| AU2007316640B2 (en) | 2006-11-10 | 2012-11-29 | Basf Se | Crystalline modification of fipronil |
| WO2008068767A2 (en) * | 2006-12-07 | 2008-06-12 | Hetero Drugs Limited | A novel crystalline form of lansoprazole |
| US20100010092A1 (en) * | 2006-12-19 | 2010-01-14 | Arless Ltd. | Use of modafinil to treat restless leg syndrome |
| US20100234468A1 (en) * | 2007-06-04 | 2010-09-16 | Abhay Gaitonde | Novel process |
| FR2923482B1 (fr) * | 2007-11-09 | 2010-01-29 | Servier Lab | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| TW200930343A (en) * | 2007-09-21 | 2009-07-16 | Organon Nv | Drug delivery system |
| WO2009045488A2 (en) * | 2007-10-02 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of armodafinil and preparation thereof |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| WO2015086489A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme B.V. | Drug delivery system for delivery of anti-virals |
| US10413504B2 (en) | 2013-12-11 | 2019-09-17 | Merck Sharp & Dohme Corp. | Intravaginal ring drug delivery system |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
| PT4210709T (pt) | 2020-09-14 | 2026-02-04 | Pharma Cinq Llc | 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿ |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1520812A (en) * | 1975-10-02 | 1978-08-09 | Lafon Labor | Benzhydrylsulphinyl derivatives |
| GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| FR2697162B1 (fr) | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| FR2706767B1 (https=) | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| FR2707637B1 (fr) * | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| IL128989A0 (en) | 1999-03-15 | 2000-02-17 | Popov Sergey | Safety trocar assembly |
| US6346548B1 (en) | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2804322B1 (fr) * | 2000-01-31 | 2002-04-19 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies |
| US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| ES2277937T3 (es) * | 2000-07-27 | 2007-08-01 | Teva Pharmaceutical Industries Ltd. | Modafinilo puro y cristalino y su procedimiento de preparacion. |
| US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| HUP0500753A3 (en) | 2001-09-07 | 2006-05-29 | Teva Pharma | Crystalline forms of valacyclovir hydrochloride |
| US6875893B2 (en) * | 2002-05-23 | 2005-04-05 | Cephalon, Inc. | Preparations of a sulfinyl acetamide |
| US6992219B2 (en) | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| AR045423A1 (es) | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| AR045314A1 (es) | 2003-05-13 | 2005-10-26 | Cephalon Inc | Composiciones farmaceuticas de analepticos y antidepresivos |
| US20040242698A1 (en) | 2003-05-13 | 2004-12-02 | Cephalon Inc. | Analeptic and antidepressant combinations |
| US20040229941A1 (en) | 2003-05-13 | 2004-11-18 | Cephalon, Inc. | Analeptic and antidepressant combinations |
| ES2330321T3 (es) | 2003-05-16 | 2009-12-09 | Cephalon France | Procedimiento de sintesis de modafinilo. |
| US20040229943A1 (en) | 2003-05-16 | 2004-11-18 | Cephalon Inc | Analeptic and drug combinations |
-
2003
- 2003-08-07 US US10/635,445 patent/US6992219B2/en not_active Expired - Fee Related
- 2003-08-08 WO PCT/IB2003/003215 patent/WO2004014846A1/en not_active Ceased
- 2003-08-08 JP JP2004527153A patent/JP4718177B2/ja not_active Expired - Fee Related
- 2003-08-08 AU AU2003253128A patent/AU2003253128B2/en not_active Ceased
- 2003-08-08 CN CN2012103955547A patent/CN102875430A/zh active Pending
- 2003-08-08 CN CNB038190850A patent/CN100506790C/zh not_active Expired - Fee Related
- 2003-08-08 NZ NZ537840A patent/NZ537840A/en not_active IP Right Cessation
- 2003-08-08 MX MXPA05001506A patent/MXPA05001506A/es active IP Right Grant
- 2003-08-08 CN CN201210395545.8A patent/CN102875429B/zh not_active Expired - Fee Related
- 2003-08-08 CA CA2494010A patent/CA2494010C/en not_active Expired - Fee Related
- 2003-08-08 CA CA2746788A patent/CA2746788C/en not_active Expired - Fee Related
- 2003-08-08 EP EP03784340A patent/EP1575915A1/en not_active Withdrawn
- 2003-08-08 CA CA2840721A patent/CA2840721C/en not_active Expired - Fee Related
- 2003-08-08 CA CA2804385A patent/CA2804385A1/en not_active Abandoned
- 2003-08-08 EP EP11171058A patent/EP2402311A1/en not_active Withdrawn
-
2005
- 2005-01-13 IL IL166301A patent/IL166301A/en not_active IP Right Cessation
- 2005-01-17 ZA ZA2005/00411A patent/ZA200500411B/en unknown
- 2005-10-12 US US11/248,442 patent/US7405323B2/en not_active Expired - Fee Related
-
2007
- 2007-12-14 US US11/956,877 patent/US7649020B2/en not_active Expired - Fee Related
-
2010
- 2010-10-20 JP JP2010235766A patent/JP5307106B2/ja not_active Expired - Fee Related
- 2010-12-13 IL IL209965A patent/IL209965A0/en unknown
- 2010-12-13 IL IL209966A patent/IL209966A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535698A5 (https=) | ||
| JP4718177B2 (ja) | モダフィニル多形相 | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| CN101896477B (zh) | 硝克柳胺化合物晶v型、其制法和其药物组合物与用途 | |
| TWI530500B (zh) | 非晶形ｎ-苄醯基-十字孢靈素、其製備方法及其用途 | |
| WO2016095650A1 (zh) | 盐酸优克那非的多晶型物及其制备方法、组合物和用途 | |
| CN104628708A (zh) | 一种阿伐那非的晶型及其制备方法、用途和药物组合物 | |
| JP2019529552A (ja) | ３−ヒドロキシ−４，５−ビス−ベンジルオキシ−６−ベンジルオキシメチル−２−フェニル−２−オキソ−２λ５−［１，２］オキサホスフィナンの結晶多形体 | |
| CN116056701A (zh) | 治疗结节硬化复合症的方法 | |
| JP2024507822A (ja) | Ｎ－（（ｒ）－２，３－ジヒドロキシプロポキシ）－３，４－ジフルオロ－２－（２－フルオロ－４－ヨードフェニルアミノ）－ベンズアミドの本質的に純粋な形態ｉｖの組成物及びその使用 | |
| JP2001521023A (ja) | ドフェチリド多形 | |
| CN109721557B (zh) | 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途 | |
| WO2021047528A1 (zh) | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 | |
| JP6522094B2 (ja) | ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用 | |
| CN101993417A (zh) | 磷酸二甲啡烷的稳定新晶型 | |
| CN101619033B (zh) | 莫达非尼多晶型 | |
| WO2026075995A1 (en) | Hydrochloric acid salt of a 5-ht2c agonist | |
| AU2024321551A1 (en) | Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl | |
| CN119912424A (zh) | (r)-3-[(苯并二氧戊环-4-基)氧基]-n,n-二甲基-3-(4-氟苯基)丙胺草酸盐的晶型及其制备方法和应用 | |
| CN104995189A (zh) | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 | |
| CN114478542A (zh) | 一种化合物晶型及其制备方法和应用 | |
| JPS63154655A (ja) | 放射線治療の補助薬として有用な置換された３−ニトロベンゼンスルホンアミド |